Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries

Abstract

Background: The number of patients with type 2 diabetes mellitus and diabetes mellitus-associated chronic kidney disease varies considerably between countries. Next to differences in genetic as well as life style risk factors, varying practices in medical care delivery might cause this diversity. Method: The PROVALID study recruited 4000 patients with type 2 diabetes mellitus at the primary level of healthcare in five European countries (Austria, Hungary, The Netherlands, Poland and Scotland). Baseline data were used to describe patient characteristics and compare the adherence to ADA (American Diabetes Association) and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines with respect to metabolic and blood pressure control, use of renin-angiotensin system-blocking agents, statins and acetylsalicylic acid between the countries. Results: About 34.8% of the population had evidence of diabetes mellitus-associated chronic kidney disease. The median HbA1c level of the cohort was 6.8% (ranging from 6.5 in Poland to 7.0% in Scotland). Mean blood pressure was 136/79 (±17/10) and significantly higher in subjects with elevated albuminuria. These individuals also were more often treated with renin-angiotensin system-blocking agents (74.1% vs 84.6%), whereas the use of statins was driven by cardiovascular comorbidity. Acetylsalicylic acid was used in only 28.9% subjects. Despite similar cardiovascular comorbidities and renal function, the use of renin-angiotensin system-blocking agents varied significantly between the countries from 66.7% to 87.4%. An even higher variability was observed for patients >40 years of age using statins (39.8%-82.7%) and administration of acetylsalicylic acid in patients older than 50 years (5.2%-43.8%). Conclusion: Our study shows that medical practice in type 2 diabetes mellitus patients with and without renal disease is different in European countries. Longitudinal follow-up will reveal if this diversity affects clinical endpoints.

Impact of the KidneyWise toolkit on chronic kidney disease referral practices in Ontario primary care: a prospective evaluation

“…Appropriate utilisation of ACE inhibitors or angiotensin receptor blockers in patients referred to nephrology was already quite high at baseline, similar to what has been previously described in a Canadian jurisdiction 31. On the other hand, use of statins was more modest, again consistent with previous work 31 32. While we did not see any change in the use of statins post-KidneyWise, there would appear to be an opportunity to improve statin utilisation in those with increased cardiovascular risk.…”

Still Asking “Which Rate Is Right?” Years Later

“…Specifically, those measures of CKD care that were least implementedproteinuria evaluation and a nephrology clinic visit for stage 4 CKD-had the greatest magnitude of variability in care delivered between facilities. Similar relationships between adherence and variability were recently described in Europe; less commonly implemented evidence-based measures, such as aspirin use (mean adherence rate of 29%), exhibited greater variability (range, 5%-43%) across countries than more commonly implemented measures, such as ACEi/ARB therapy (mean adherence rate of 76%; range, 67%-87%) (7). These observations lend credence to the idea that practice pattern variation is closely related to local experiences, culture, and resources.…”

Planned primary health care asthma contacts during 12-year follow-up after Finnish National Asthma Programme: focus on spirometry

“…Evidence-based medicine and guidelines have improved the quality of health care, but still suboptimal adherence to care guidelines is a common worldwide problem seen not only with asthma 2-5 and chronic obstructive pulmonary disease [52][53][54] but also with other common chronic conditions, such as cardiovascular diseases and diabetes [55][56][57][58][59] . GPs generally deal with multimorbid patients.…”